Macular degeneration, also known as age-related macular degeneration (AMD), is a leading cause of vision loss in people over the age of 50. It occurs when the central portion of the retina, known as the macula, begins to deteriorate. This can result in a loss of central vision, making it difficult to read, drive, or perform other activities that require sharp vision.
The global macular degeneration treatment market recorded a CAGR of 6.2% in the last 9 years from 2012 to 2021 and reached a market value of around US$ 8.6 Bn in 2021. The market is estimated to surge ahead at a CAGR of 7.4% to reach US$ 18.8 Bn by the end of 2032.
As assessed by Persistence Market Research, anti-vascular endothelial growth factors accounted for a market share of 60.8% in 2021. Overall, macular degeneration treatment accounts for approximately 18.7% revenue share of the global neurodegenerative disorders treatment market, which was valued at around US$ 45.9 Bn at the end of 2021.
Request For Free Sample Report of “Macular Degeneration Treatment Market”@ https://www.persistencemarketresearch.com/samples/33174
The treatment market for macular degeneration is expected to grow in the coming years, driven by the aging population and increasing prevalence of the condition. There are several treatment options available for AMD, including dietary supplements, medications, and surgery. These treatments can help to slow the progression of the disease and improve vision in some cases.
One of the key players in the macular degeneration treatment market is the pharmaceutical industry, which is developing new medications to treat the condition. These medications may be taken orally or injected directly into the eye.
Companies
- Hoffmann-La Roche Ltd.
- Novartis AG
- Bayer AG
- Pfizer Inc.
- Bausch Health Companies Inc.
- Regeneron Pharmaceuticals Inc.
- Amgen Inc.
- Biogen
- Samsung Bioepis
- Santen Pharmaceutical Co., Ltd.
Buy Full Report Now @ https://www.persistencemarketresearch.com/checkout/33174
In addition to pharmaceutical treatments, there is also a growing market for non-pharmaceutical treatments such as low vision aids and rehabilitation services. These treatments can help individuals with AMD to better manage their condition and maintain independence.
Overall, the market for macular degeneration treatment is expected to continue growing in the coming years as more people are diagnosed with the condition and new treatments become available.
Competitive Landscape
Major macular degeneration drug manufacturers are adopting strategies such as research collaborations for the development of novel products. Moreover, several market players have a strong pipeline for therapeutics, intended to be launched through patient protection and licensing.
Instances include:
Mosaic Biosciences and Ocular Therapeutix announced a research agreement in June 2021 to develop a medication to treat individuals with dry age-related macular degeneration. This collaboration strengthens the company’s R&D portfolio and offers the business a substantial growth opportunity.
Novartis AG received European Commission authorization to market Beovu in February 2020. It is an anti-VEGF medication used to treat patients with wet AMD.
Request Customization @ https://www.persistencemarketresearch.com/request-customization/33174
Macular Degeneration Treatment Industry Research Segmentation
By Drug:
- Anti-vascular Endothelial Growth Factors
- Others
By Indication:
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
By Route of Administration:
- Intravenous Route
- Intravitreal Route
- Others
By Distribution Channel:
- Hospitals
- Ophthalmology Clinics
- Ambulatory Surgical Centers
- Others
About Us
Persistence Market Research’s Expertise in Life Sciences and Transformational Health
Our expert team of industry analysts comprising management graduates, medical professionals, engineers, and project managers provides insights on emerging therapy areas, diagnostic tools, medical devices and components, reimbursement and market access, biotechnology, and life science research products and services to equip decision-makers with sound inputs and strategic recommendations. Click here to learn more about how we zero in on the critical aspects of this industry.
Contact Us:
Persistence Market Research
Japan
Persistence Market Research
1-2-1 Kinshi Arca Central Building 14/F Tokyo, 130-0013 Japan
Call 0800-222-1088
United States
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – [email protected]